Contact a Rep
Patients HCPs
This site is for US Healthcare Professionals only.
Patient image with text: For your patients with PSMA+ mCRPC, strive for PLUVICTORY. Give your patients a chance for more tomorrows with PLUVICTO. That’s a Victory. Significant median OS demonstrated in the VISION trial: 15.3 months with PLUVICTO + BSOC vs 11.3 months with BSOC alone (HR=0.62; 95% CI, 0.52-0.74; P<0.001)

PLUVICTO is the first and only PSMA-targeted radioligand therapy to significantly improve OS in a phase 3 mCRPC trial1,2

PLUVICTO targets PSMA, a biomarker overexpressed in more than 80% of men with prostate cancer1,3,4

PLUVICTO significantly improved OS1,2

  • Median OS was 15.3 months with PLUVICTO + BSOC vs 11.3 months with BSOC alone (HR=0.62 [95% CI, 0.52-0.74]; P<0.001)1,2

PLUVICTO has an established safety profile1

  • Most common ARs (≥20%) with PLUVICTO + BSOC were fatigue, dry mouth, nausea, anemia, decreased appetite, and constipation1

ARs, adverse reactions; BSOC, best standard of care; HR, hazard ratio; mCRPC, metastatic castration-resistant prostate cancer; OS, overall survival; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive.

References: 1. Pluvicto. Prescribing information. Novartis Pharmaceuticals Corp. 2. Sartor O, de Bono J, Chi KN, et al; VISION Investigators. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091-1103. doi:10.1056/NEJMoa2107322 3. Hupe MC, Philippi C, Roth D, et al. Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis. Front Oncol. 2018;8:623. doi:10.3389/fonc.2018.00623 4. Pomykala KL, Czernin J, Grogan TR, Armstrong WR, Williams J, Calais J. Total-body 68Ga-PSMA-11 PET/CT for bone metastasis detection in prostate cancer patients: potential impact on bone scan guidelines. J Nucl Med. 2020;61(3):405-411. doi:10.2967/jnumed.119.230318